High body mass index predicts multiple prostate cancer lymph node metastases after radical prostatectomy and extended pelvic lymph node dissection.


Journal

Asian journal of andrology
ISSN: 1745-7262
Titre abrégé: Asian J Androl
Pays: China
ID NLM: 100942132

Informations de publication

Date de publication:
Historique:
pubmed: 28 7 2019
medline: 22 6 2021
entrez: 27 7 2019
Statut: ppublish

Résumé

Our aim is to evaluate the association between body mass index (BMI) and preoperative total testosterone (TT) levels with the risk of single and multiple metastatic lymph node invasion (LNI) in prostate cancer patients undergoing radical prostatectomy and extended pelvic lymph node dissection. Preoperative BMI, basal levels of TT, and prostate-specific antigen (PSA) were evaluated in 361 consecutive patients undergoing radical prostatectomy with extended pelvic lymph node dissection between 2014 and 2017. Patients were grouped into either nonmetastatic, one, or more than one metastatic lymph node invasion groups. The association among clinical factors and LNI was evaluated. LNI was detected in 52 (14.4%) patients: 28 (7.8%) cases had one metastatic node and 24 (6.6%) had more than one metastatic node. In the overall study population, BMI correlated inversely with TT (r = -0.256; P < 0.0001). In patients without metastases, BMI inversely correlated with TT (r = -0.282; P < 0.0001). In patients with metastasis, this correlation was lost. In the overall study population, BMI (odds ratio [OR] = 1.268; P = 0.005) was the only independent clinical factor associated with the risk of multiple metastatic LNI compared to cases with one metastatic node. In the nonmetastatic group, TT was lower in patients with BMI >28 kg m

Identifiants

pubmed: 31347517
pii: 263431
doi: 10.4103/aja.aja_70_19
pmc: PMC7275807
doi:

Substances chimiques

Testosterone 3XMK78S47O
Prostate-Specific Antigen EC 3.4.21.77

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

323-329

Déclaration de conflit d'intérêts

None

Références

BJU Int. 2009 Apr;103(7):877-82
pubmed: 19007372
Cancer Epidemiol. 2016 Apr;41:8-15
pubmed: 26775081
J Urol. 1998 Dec;160(6 Pt 2):2418-24
pubmed: 9817395
World J Mens Health. 2019 Sep;37(3):288-295
pubmed: 30209899
JAMA. 1998 Sep 16;280(11):969-74
pubmed: 9749478
Neoplasia. 2006 Dec;8(12):1083-9
pubmed: 17217626
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
Turk J Urol. 2017 Sep;43(3):289-296
pubmed: 28861300
Eur Urol. 2017 Apr;71(4):618-629
pubmed: 27568654
J Clin Endocrinol Metab. 2007 Feb;92(2):405-13
pubmed: 17090633
J Robot Surg. 2019 Feb;13(1):83-89
pubmed: 29737495
BJU Int. 2018 May;121 Suppl 3:9-21
pubmed: 29460324
Urol Int. 2017;99(4):392-399
pubmed: 28486228
Int J Urol. 2014 Oct;21(10):980-6
pubmed: 24865433
Arch Pathol Lab Med. 2009 Oct;133(10):1568-76
pubmed: 19792046
Lancet Oncol. 2002 Sep;3(9):565-74
pubmed: 12217794
J Clin Endocrinol Metab. 2008 Jul;93(7):2737-45
pubmed: 18270261
Urol Oncol. 2013 Oct;31(7):997-1002
pubmed: 21925906
Curr Urol. 2017 Aug;10(3):118-125
pubmed: 28878593
Eur Urol. 2017 Jul;72(1):84-109
pubmed: 28126351
Transl Androl Urol. 2017 Jun;6(3):566-579
pubmed: 28725600
Tumori. 2017 May 12;103(3):299-306
pubmed: 27716882
CA Cancer J Clin. 1972 Jul-Aug;22(4):232-40
pubmed: 4625049
Int J Cancer. 2017 Nov 1;141(9):1783-1793
pubmed: 28699177
Eur J Cancer. 2015 Jun;51(9):1164-87
pubmed: 24120180
Tumori. 2018 Aug;104(4):307-311
pubmed: 29714659
BMC Cancer. 2019 Jan 18;19(1):87
pubmed: 30658612
Endocr Rev. 2017 Aug 1;38(4):302-324
pubmed: 28673039
BJU Int. 2019 Jul;124(1):69-75
pubmed: 30347135
J Clin Endocrinol Metab. 2010 Oct;95(10):4542-8
pubmed: 20926540
Prostate Cancer Prostatic Dis. 2017 Jun;20(2):146-155
pubmed: 28220805
Eur Urol. 2012 Mar;61(3):480-7
pubmed: 22078338
Am J Surg Pathol. 2016 Feb;40(2):244-52
pubmed: 26492179
J Natl Cancer Inst. 2016 Oct 20;109(3):
pubmed: 27754927
J Urol. 2003 Jun;169(6):2289-92
pubmed: 12771773
Asian J Androl. 2016 Jul-Aug;18(4):543-8
pubmed: 27080479

Auteurs

Antonio B Porcaro (AB)

Department of Urology, Azienda Ospedaliera Universitaria Integrata Verona, Verona 37126, Italy.

Alessandro Tafuri (A)

Department of Urology, Azienda Ospedaliera Universitaria Integrata Verona, Verona 37126, Italy.
USC Institute of Urology and Catherine and Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.

Marco Sebben (M)

Department of Urology, Azienda Ospedaliera Universitaria Integrata Verona, Verona 37126, Italy.

Tania Processali (T)

Department of Urology, Azienda Ospedaliera Universitaria Integrata Verona, Verona 37126, Italy.

Marco Pirozzi (M)

Department of Urology, Azienda Ospedaliera Universitaria Integrata Verona, Verona 37126, Italy.

Nelia Amigoni (N)

Department of Urology, Azienda Ospedaliera Universitaria Integrata Verona, Verona 37126, Italy.

Riccardo Rizzetto (R)

Department of Urology, Azienda Ospedaliera Universitaria Integrata Verona, Verona 37126, Italy.

Aliasger Shakir (A)

USC Institute of Urology and Catherine and Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.

Maria Angela Cerruto (MA)

Department of Urology, Azienda Ospedaliera Universitaria Integrata Verona, Verona 37126, Italy.

Matteo Brunelli (M)

Department of Pathology, Azienda Ospedaliera Universitaria Integrata Verona, Verona 37126, Italy.

Salvatore Siracusano (S)

Department of Urology, Azienda Ospedaliera Universitaria Integrata Verona, Verona 37126, Italy.

Walter Artibani (W)

Department of Urology, Azienda Ospedaliera Universitaria Integrata Verona, Verona 37126, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH